<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01665326</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00001562</org_study_id>
    <secondary_id>U54NS065768</secondary_id>
    <nct_id>NCT01665326</nct_id>
  </id_info>
  <brief_title>Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease</brief_title>
  <official_title>Determination of Cross-Reactive Immunological Material (CRIM) Status and Longitudinal Follow-up of Individuals With Pompe Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rare Diseases Clinical Research Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a longitudinal natural history study of Infantile Pompe disease. The investigators
      will regularly collect and review medical information regarding the diagnosis of Pompe
      disease, response to enzyme replacement (ERT) using alglucosidase alfa (Lumizyme/Myozyme) and
      response to immunosuppressive therapy in cases at risk for developing or those who have
      developed high and sustained antibodies to ERT. A subset of de-identified information about
      the natural history of Pompe disease and the response to treatment will be incorporated into
      the Lysosomal Disease Network (LDN) disease registry. The LDN is a nonprofit organization of
      scientists located around the world whose research focuses on Lysosomal disease.

      The specific aims of this study are:

        1. To determine and correlate Cross-Reactive Immunological Material (CRIM) status with the
           GAA gene mutations found on these patients

        2. To validate an approach for determining CRIM status from whole blood sample, with the
           gold standard determination of CRIM status by skin fibroblasts and mutation analysis

        3. To explore the clinical treatment response and natural history of CRIM-positive and
           CRIM-negative Pompe disease patients with and without immune modulation

        4. To investigate the role of immune response to treatment
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infantile-onset Pompe disease is an inherited disorder caused by lack of or defect in the
      enzyme acid alpha-glucosidase (GAA). GAA enzyme deficiency causes glycogen to build up and
      damage cells throughout the body, especially in the heart and muscles, which is normally
      diagnosed within the first months of life. Current treatment for Pompe disease involves
      enzyme replacement therapy (ERT) using the drug alglucosidase alfa (Lumizyme/Myozyme), which
      provides a form of the GAA enzyme to replace the enzyme that is missing or not working
      properly in the patient's blood.

      In this study, the investigators will learn about the patient's ability to tolerate ERT.
      Cross-Reactive Immunological Material (CRIM) is a measurement of natural GAA production and
      an important factor that affects how patients respond to ERT with Myozyme. Children who
      produce some natural GAA are classified as CRIM positive (+), while children who do not
      produce any natural GAA are classified as CRIM negative (-). Children who are CRIM+ generally
      tolerate ERT well. But, children who are CRIM-, and some children classified as CRIM+, have a
      poor response to ERT due to complications from an immune response against the drug.
      Treatments are currently being developed to stop this immune response and prevent
      complications from ERT.

      This is a longitudinal natural history study of Infantile Pompe disease. The investigators
      will regularly collect and review medical information regarding the diagnosis of Pompe
      disease, response to enzyme replacement (ERT) using alglucosidase alfa (Lumizyme/Myozyme) and
      response to immunosuppressive therapy in cases at risk for developing or those who have
      developed high and sustained antibodies to ERT. A subset of de-identified information about
      the natural history of Pompe disease and the response to treatment will be incorporated into
      the Lysosomal Disease Network (LDN) disease registry. The LDN is a nonprofit organization of
      scientists located around the world whose research focuses on Lysosomal disease.

      The specific aims of this study are:

        1. To determine and correlate Cross-Reactive Immunological Material (CRIM) status with the
           GAA gene mutations found on these patients

        2. To validate an approach for determining CRIM status from whole blood sample, with the
           gold standard determination of CRIM status by skin fibroblasts and mutation analysis

        3. To explore the clinical treatment response and natural history of CRIM-positive and
           CRIM-negative Pompe disease patients with and without immune modulation

        4. To investigate the role of immune response to treatment
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical response to enzyme replacement therapy (ERT) using alglucosidase alfa (Myozyme)</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Medical records will be tracked for up to 10 years to follow clinical response to ERT. This will allow us to gain an understanding of CRIM status in relation to clinical outcome and development for these subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response to Immune Tolerance Induction (ITI)</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Medical records will be tracked for up to 10 years to follow clinical response to Immune Tolerance Induction (ITI) for patients who are CRIM- or CRIM+ with high antibody titers. This will allow us to increase our understanding of the history of Pompe disease in relation to treatment interventions and the role of high antibody titers in terms of patient outcome in order to develop strategies to ameliorate the immune response and other factors that may affect response to ERT.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Pompe Disease</condition>
  <arm_group>
    <arm_group_label>Infantile Pompe disease</arm_group_label>
    <description>Individuals with a confirmed diagnosis of Infantile Pompe disease</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>This is a longitudinal study focused on the emerging natural history of Infantile Pompe disease, response to ERT using alglucosidase alfa (Myozyme) and response to Immune Tolerance Induction (ITI).</description>
    <arm_group_label>Infantile Pompe disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study subjects will be babies/children with a confirmed diagnosis of infantile-onset Pompe
        disease who are:

          1. seen by the clinical staff of Duke Division of Medical Genetics, or

          2. whose physician or parent contacts the Duke Division of Medical Genetics with the wish
             to participate in this CRIM research study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of infantile, atypical or juvenile onset Pompe disease

          -  Must have a parent or guardian provide written informed consent

        Exclusion Criteria:

          -  Age 18 or older
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priya S Kishnani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ankit K Desai, MBBS</last_name>
    <phone>919-613-6310</phone>
    <email>ankit.desai@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie DeArmey, MHS, PA-C</last_name>
    <phone>919-681-1946</phone>
    <email>Stephanie.Dearmey@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ankit K Desai, MBBS</last_name>
      <phone>919-613-6310</phone>
      <email>ankit.desai@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie DeArmey, MHS, PA-C</last_name>
      <phone>919-681-1946</phone>
      <email>Stephanie.Dearmey@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Priya S Kishnani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Banugaria SG, Prater SN, Ng YK, Kobori JA, Finkel RS, Ladda RL, Chen YT, Rosenberg AS, Kishnani PS. The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: lessons learned from infantile Pompe disease. Genet Med. 2011 Aug;13(8):729-36. doi: 10.1097/GIM.0b013e3182174703.</citation>
    <PMID>21637107</PMID>
  </results_reference>
  <results_reference>
    <citation>Messinger YH, Mendelsohn NJ, Rhead W, Dimmock D, Hershkovitz E, Champion M, Jones SA, Olson R, White A, Wells C, Bali D, Case LE, Young SP, Rosenberg AS, Kishnani PS. Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease. Genet Med. 2012 Jan;14(1):135-42. doi: 10.1038/gim.2011.4.</citation>
    <PMID>22237443</PMID>
  </results_reference>
  <results_reference>
    <citation>Mendelsohn NJ, Messinger YH, Rosenberg AS, Kishnani PS. Elimination of antibodies to recombinant enzyme in Pompe's disease. N Engl J Med. 2009 Jan 8;360(2):194-5. doi: 10.1056/NEJMc0806809.</citation>
    <PMID>19129538</PMID>
  </results_reference>
  <results_reference>
    <citation>Berrier KL, Kazi ZB, Prater SN, Bali DS, Goldstein J, Stefanescu MC, Rehder CW, Botha EG, Ellaway C, Bhattacharya K, Tylki-Szymanska A, Karabul N, Rosenberg AS, Kishnani PS. CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy. Genet Med. 2015 Nov;17(11):912-8. doi: 10.1038/gim.2015.6. Epub 2015 Mar 5. Erratum in: Genet Med. 2015 Jul;17(7):596. Rosenburg, Amy S [corrected to Rosenberg, Amy S].</citation>
    <PMID>25741864</PMID>
  </results_reference>
  <results_reference>
    <citation>Banugaria SG, Prater SN, Patel TT, Dearmey SM, Milleson C, Sheets KB, Bali DS, Rehder CW, Raiman JA, Wang RA, Labarthe F, Charrow J, Harmatz P, Chakraborty P, Rosenberg AS, Kishnani PS. Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. PLoS One. 2013 Jun 25;8(6):e67052. doi: 10.1371/journal.pone.0067052. Print 2013.</citation>
    <PMID>23825616</PMID>
  </results_reference>
  <results_reference>
    <citation>Kazi ZB, Desai AK, Troxler RB, Kronn D, Packman S, Sabbadini M, Rizzo WB, Scherer K, Abdul-Rahman O, Tanpaiboon P, Nampoothiri S, Gupta N, Feigenbaum A, Niyazov DM, Sherry L, Segel R, McVie-Wylie A, Sung C, Joseph AM, Richards S, Kishnani PS. An immune tolerance approach using transient low-dose methotrexate in the ERT-na√Øve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease. Genet Med. 2019 Apr;21(4):887-895. doi: 10.1038/s41436-018-0270-7. Epub 2018 Sep 14.</citation>
    <PMID>30214072</PMID>
  </results_reference>
  <results_reference>
    <citation>Desai AK, Walters CK, Cope HL, Kazi ZB, DeArmey SM, Kishnani PS. Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation. Mol Genet Metab. 2018 Feb;123(2):92-96. doi: 10.1016/j.ymgme.2017.12.435. Epub 2017 Dec 23.</citation>
    <PMID>29289479</PMID>
  </results_reference>
  <results_reference>
    <citation>McIntosh PT, Hobson-Webb LD, Kazi ZB, Prater SN, Banugaria SG, Austin S, Wang R, Enterline DS, Frush DP, Kishnani PS. Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy. Mol Genet Metab. 2018 Feb;123(2):85-91. doi: 10.1016/j.ymgme.2017.10.005. Epub 2017 Oct 13.</citation>
    <PMID>29050825</PMID>
  </results_reference>
  <results_reference>
    <citation>Rairikar M, Kazi ZB, Desai A, Walters C, Rosenberg A, Kishnani PS. High dose IVIG successfully reduces high rhGAA IgG antibody titers in a CRIM-negative infantile Pompe disease patient. Mol Genet Metab. 2017 Sep;122(1-2):76-79. doi: 10.1016/j.ymgme.2017.05.006. Epub 2017 May 18.</citation>
    <PMID>28648664</PMID>
  </results_reference>
  <results_reference>
    <citation>Kazi ZB, Desai AK, Berrier KL, Troxler RB, Wang RY, Abdul-Rahman OA, Tanpaiboon P, Mendelsohn NJ, Herskovitz E, Kronn D, Inbar-Feigenberg M, Ward-Melver C, Polan M, Gupta P, Rosenberg AS, Kishnani PS. Sustained immune tolerance induction in enzyme replacement therapy-treated CRIM-negative patients with infantile Pompe disease. JCI Insight. 2017 Aug 17;2(16). pii: 94328. doi: 10.1172/jci.insight.94328. eCollection 2017 Aug 17.</citation>
    <PMID>28814660</PMID>
  </results_reference>
  <results_reference>
    <citation>Spiridigliozzi GA, Keeling LA, Stefanescu M, Li C, Austin S, Kishnani PS. Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: A longitudinal follow-up. Mol Genet Metab. 2017 Jun;121(2):127-137. doi: 10.1016/j.ymgme.2017.04.014. Epub 2017 May 1.</citation>
    <PMID>28495044</PMID>
  </results_reference>
  <results_reference>
    <citation>Kazi ZB, Prater SN, Kobori JA, Viskochil D, Bailey C, Gera R, Stockton DW, McIntosh P, Rosenberg AS, Kishnani PS. Durable and sustained immune tolerance to ERT in Pompe disease with entrenched immune responses. JCI Insight. 2016 Jul 21;1(11). pii: 86821. doi: 10.1172/jci.insight.86821.</citation>
    <PMID>27493997</PMID>
  </results_reference>
  <results_reference>
    <citation>Bali DS, Goldstein JL, Rehder C, Kazi ZB, Berrier KL, Dai J, Kishnani PS. Clinical Laboratory Experience of Blood CRIM Testing in Infantile Pompe Disease. Mol Genet Metab Rep. 2015 Dec 1;5:76-79.</citation>
    <PMID>26693141</PMID>
  </results_reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 13, 2012</study_first_submitted>
  <study_first_submitted_qc>August 14, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2012</study_first_posted>
  <last_update_submitted>August 14, 2019</last_update_submitted>
  <last_update_submitted_qc>August 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pompe disease</keyword>
  <keyword>Glycogen Storage Disease Type II</keyword>
  <keyword>Acid Maltase Deficiency</keyword>
  <keyword>CRIM Status</keyword>
  <keyword>Acid Alpha-Glucosidase Deficiency</keyword>
  <keyword>Alglucosidase alfa</keyword>
  <keyword>Myozyme</keyword>
  <keyword>Enzyme replacement therapy</keyword>
  <keyword>Immune Tolerance Induction</keyword>
  <keyword>Lumizyme</keyword>
  <keyword>Immunomodulation</keyword>
  <keyword>Anti-drug antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glycogen Storage Disease Type II</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

